Why the study?
The 2023 ESC guidelines introduced a first-time Class I recommendation for genetic testing in cardiomyopathies, prompting the Italian CardioGenetics Group to provide expert consensus guidance on integrating a structured genetic pathway into clinical practice.
This Italian consensus statement provides structured guidance for implementing the 2023 ESC Class I (Level of Evidence B) recommendation for genetic testing in the diagnostic workup and management of cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Enables structured clinical adoption of ESC Class I genetic testing in cardiomyopathies; extends consensus with phenotype-first pathways and ACMG variant protocols.
This consensus document results from a three-phase process conducted among Italian geneticists, experts in cardiovascular genetics. The proposal was first presented and discussed at the annual meeting of the Italian CardioGenetics Group (ICGG) (2025), then drafted, circulated, and finally revised and approved by consensus of all contributing members. The 2023 guidelines of the European Society of Cardiology introduced, for the first time, a Class I Level of Evidence B recommendation for genetic testing in cardiomyopathies, formally integrating a structured genetic pathway into the diagnostic process and assigning it a central clinical role for patients and their families. This document provides expert statements on: the 2023 ESC recommendations on genetic testing in cardiomyopathies; the guidance of the European Society of Human Genetics and the Italian Society of Human Genetics (SIGU) regarding clinical genetic testing within the National Health System; the ESC phenotype-first diagnostic approach; tailored genetic testing strategies and tools; positions on direct-to-consumer genetic testing (DTC-GT); quality standards in accordance with national and international regulations; cautious interpretation of variants of uncertain significance; gene curation, variant classification and reclassification according to the American College of Medical Genetics and Genomics criteria; definition of completeness of genetic testing in clinical practice; and the role of genetic testing in reproductive counselling and preimplantation genetic testing.
No takes yet. Share an insight, caveat, or question.
Grasso et al. (2026) studied Cardiomyopathies. Structured genetic testing pathway in cardiomyopathies was evaluated. The Italian CardioGenetics Group consensus statement integrates the 2023 ESC Class I (Level B) recommendation for genetic testing into structured clinical pathways for cardiomyopathies.
Synapse has enriched 10 related papers. Consider them for comparative context: